Ispronicline

Ispronicline

Clinical data
ATC code	none
Identifiers
IUPAC name (2S,4E)-5-(5-isopropoxypyridin-3-yl)-N-methylpent-4-en-2-amine
CAS Number	252870-53-4 checkY
PubChem CID	9824145
ChemSpider	7999892 ☒N
UNII	3E05NBH9V5
KEGG	D08935 checkY
E number	{{#property:P628}}
CompTox Dashboard (EPA)	{{#property:P3117}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C14H22N2O
Molar mass	234.343 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@@H](C/C=C/C1=CC(=CN=C1)OC(C)C)NC
InChI InChI=1S/C14H22N2O/c1-11(2)17-14-8-13(9-16-10-14)7-5-6-12(3)15-4/h5,7-12,15H,6H2,1-4H3/b7-5+/t12-/m0/s1 ☒N Key:RPCVIAXDAUMJJP-PZBABLGHSA-N ☒N
☒NcheckY (what is this?)  (verify)

Ispronicline (TC-1734, AZD-3480) is an experimental drug which acts as a partial agonist at neural nicotinic acetylcholine receptors. It progressed to phase II clinical trials for the treatment of dementia and Alzheimer's disease, but is no longer under development.

It has also progressed to phase II as a potential treatment for ADHD. With dosages of 50 mg/day showing a significant improvement in ADHD symptoms

Ispronicline is subtype-selective, binding primarily to the α4β2 subtype. It has antidepressant, nootropic and neuroprotective effects.

Early stage clinical trials showed that ispronicline was well tolerated, with the main side effects being dizziness and headache. However, mid-stage clinical trials failed to show sufficient efficacy to continue development as a pharmaceutical drug.

See also

• Rivanicline